---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-007323"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:02:15.133789+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma enters new employment agreements with CEO, CFO, COO; CEO severance of $14M USD

## Summary
- CEO Dr. Slilaty: $543,753 CAD base salary, 5% or CPI annual increase, $14M USD severance for termination without cause or for good reason.
- CFO Camille Sebaaly: $411,000 CAD base salary, 5% or CPI annual increase, $2M CAD severance for termination without cause.
- COO Dr. Merzouki: $328,800 CAD base salary, 5% or CPI annual increase, $2M CAD severance for termination without cause.
- All three executives to devote 90% of time to subsidiary Nora Pharma Inc.; agreements effective retroactive to January 1, 2024.
- CEO's $14M USD severance is substantially larger relative to base salary than CFO and COO severance of $2M CAD each.

## SEC filing metadata
- accession: 0001683168-24-007323
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824007323/0001683168-24-007323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824007323/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-007323
- JSON: https://secwatch.observer/filing/0001683168-24-007323.json
- Plain text: https://secwatch.observer/filing/0001683168-24-007323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.